| lisdexamfetamine / Generic mfg. |
| Recruiting | 4 | 62 | | | University of Sydney, Shire International GmbH | Binge-Eating Disorder | | | | |
ACTRN12621000045819: An open-label trial of oral lisdexamfetamine for the treatment of acute methamphetamine withdrawal |
|
|
| Recruiting | 4 | 15 | | | St Vincent's Hospital Sydney, The National Centre for Clinical Research on Emerging Drugs | Acute methamphetamine withdrawal | | | | |
NCT01413165: Phase 4, Open Label, Multicentre, 2 Year Safety Study of Lisdexamfetamine Dimesylate in Children/Adolescents With ADHD |
|
|
| Not yet recruiting | 4 | 12 | Europe | Lisdexamfetamine dimesylate, SPD 489 | Maastricht University Medical Center, Shire Development LLC | Attention Deficit Disorder With Hyperactivity | 08/13 | 12/13 | | |
NCT03337646: Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism |
|
|
| Completed | 4 | 48 | Canada | Lisdexamfetamine Dimesylate, Vyvanse | JPM van Stralen Medicine Professional, Shire | Attention Deficit Hyperactivity Disorder, Autism Spectrum Disorder | 03/23 | 03/23 | | |
| Recruiting | 4 | 10 | US | Stimulant, Adderall, Concerta, Aptensio, Daytrana, Metadate, Quillivant, Ritalin, Focalin, Vyvanse | Matthew J O'Brien, PhD, BCBA-D | Attention Deficit Hyperactivity Disorder, Problem Behavior | 01/25 | 01/25 | | |
